Being close enough to patients to care is as critical as remaining distant enough from a pathogen to be safe. This strategy simultaneously frustrates and supports public trust.
AMA J Ethics. 2020;22(1):E22-27. doi:
10.1001/amajethics.2020.22.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Dr Christopher Whaley joins Ethics Talk to discuss his article, coauthored with Dr Austin Frakt: “If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important?”
Dr Kevin Schulman joins Ethics Talk to discuss his article, coauthored with Dr Barak Richman: “Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm.”